AMD Clinical Trial - Retinal Imaging Using NOTAL-OCT V2.5

Status Completed

Clinical Trial Summary

Primary objectives: To compare between retinal measurements, done by the NOTAL-OCT V2.5 device and a commercial OCT. Secondary objectives: 1. To evaluate the level of agreement between the NOTAL-OCT V2.5 and a commercial OCT in the presence of fluid as identified in the OCT images, in the central 10 degrees of the macula. 2. To evaluate the repeatability of the NOTAL-OCT V2.5

Clinical Trial Description

Study population: 1. AMD population - intermediate and advanced AMD (with active and nonactive CNV) 2. DR population. Patient with and without DME ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03600519
Study type	Observational
Source	Notal Vision Inc.
Contact
Status	Completed
Phase
Start date	July 22, 2018
Completion date	January 1, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01432847` - Cell Collection to Study Eye Diseases
Recruiting	`NCT03893474` - Quality-Assured Follow-up of Quiescent Neovascular Age -Related maculaR dEgeneration by Non-medical Practitioners	N/A
Completed	`NCT00971464` - Low Vision Study Comparing EV Training vs. CCTV for AMD Rehabilitation	Phase 2
Terminated	`NCT00332657` - Anecortave Acetate Risk Reduction Trial (AART)	Phase 3
Recruiting	`NCT04796545` - Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration	N/A
Completed	`NCT01766596` - Study the Signs of Ocular Degeneration in a Population Cohort (Dijon 3C Montrachet Cohort)	N/A
Completed	`NCT03322930` - Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)
Completed	`NCT01778491` - AMD Phenotype and Genotype Study
Completed	`NCT01016873` - INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD	Phase 2
Active, not recruiting	`NCT03845582` - Phase 3 Study of ALK-001 in Geographic Atrophy	Phase 3
Completed	`NCT03372746` - Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration
Completed	`NCT03367767` - Age-Related Eye Disease Study 2 (AREDS2) 10-year Follow-On
Terminated	`NCT00333216` - Anecortave Acetate Risk-Reduction Trial (AART)	Phase 3
Completed	`NCT01570790` - Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration	Phase 1/Phase 2
Completed	`NCT00346866` - Anecortave Acetate Versus Placebo in AMD Patients Following PDT	Phase 2
Withdrawn	`NCT00726466` - Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration	Phase 1
Completed	`NCT00306488` - OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration	Phase 2
Terminated	`NCT02348359` - X-82 to Treat Age-related Macular Degeneration	Phase 2
Completed	`NCT01632527` - Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD)	Phase 1/Phase 2
Withdrawn	`NCT01339949` - Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)	N/A